NEW YORK--(BUSINESS WIRE)--
The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Meridian Bioscience, Inc. ("Meridian Bioscience") (NASDAQ: VIVO) between March 25, 2016 and July 13, 2017. You are hereby notified that a securities class action lawsuit has been commenced in United States District Court for the Southern District of Ohio. To get more information go to:
http://www.zlk.com/plsra-c/meridian-bioscience-inc?wire=2
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Defendant’s lead tests provide inaccurate results; and (ii) as a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Meridian Bioscience you have until January 16, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171128006360/en/
